Director and Officer Joshua Barry Cohen filed a Form 144 notice of proposed sale of 100,000 shares of Amylyx Pharmaceuticals Inc common stock on November 9, 2026, pursuant to Rule 144 under the Securities Act of 1933.

Key Highlights

  • Proposed sale: Joshua Barry Cohen intends to sell 100,000 shares of Amylyx Pharmaceuticals common stock.
  • Aggregate market value: The 100,000 shares carry an aggregate market value of $2,950,000.00, according to the filing.
  • Shares outstanding: The filing reports 128,562,904 shares of common stock outstanding.
  • Acquisition origin: The shares to be sold were acquired on January 13, 2014, as Founders Shares from the issuer.
  • Prior sales: Cohen sold 30,464 shares on September 10, 2026, for gross proceeds of $980,503.90, the filing disclosed.
  • Trading plan: The filing indicates a Rule 10b5-1 plan or instruction was adopted on May 11, 2026.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is listed as the broker.

Cohen's Proposed Sale of Founders Shares on NASDAQ:AMLX

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 9, 2026, Joshua Barry Cohen, identified as both a Director and Officer of Amylyx Pharmaceuticals Inc (NASDAQ:AMLX), has provided notice of his intent to sell 100,000 shares of the company's common stock. The approximate date of sale listed in the filing is November 9, 2026, and the exchange named is NASDAQ.

The filing discloses that the shares proposed for sale were originally acquired on January 13, 2014, through a Founders Shares transaction with the issuer, with payment described as "N/A." The aggregate market value of the 100,000 shares is stated as $2,950,000.00. Total shares of common stock outstanding are reported as 128,562,904.

The filing also reports prior sales activity within the past three months: Cohen sold 30,464 shares on September 10, 2026, generating gross proceeds of $980,503.90. The filing notes the adoption date of a Rule 10b5-1 plan or trading instruction as May 11, 2026. By signing the notice, Cohen represented that he does not know any material adverse information regarding the current and prospective operations of Amylyx Pharmaceuticals that has not been publicly disclosed, as stated in the filing's attestation language.

What Was Disclosed

Amylyx Pharmaceuticals Director and Officer Joshua Barry Cohen filed a Form 144 notice proposing to sell 100,000 Founders Shares of common stock with an aggregate market value of $2,950,000.00, under a Rule 10b5-1 plan adopted May 11, 2026.